usiness year <strong>2012</strong>consolidated financial statementsC. H. <strong>Boehringer</strong> Sohn Grundstücksverwaltung GmbH & Co. KG<strong>Boehringer</strong> <strong>Ingelheim</strong>Auslandsbeteiligungs GmbHargentina D Rgreece D Pnew zealandDturkeyD<strong>Boehringer</strong> <strong>Ingelheim</strong> S.A.,Buenos Aires<strong>Boehringer</strong> <strong>Ingelheim</strong> Ellas AE,Athens<strong>Boehringer</strong> <strong>Ingelheim</strong>(N.Z.) Ltd., Auckland<strong>Boehringer</strong> <strong>Ingelheim</strong> IlacTicaret A.S., IstanbulaustraliaDindonesia D PportugalDunited kingdomD<strong>Boehringer</strong> <strong>Ingelheim</strong> Pty. Ltd.,North Rydebrazil D P<strong>Boehringer</strong> <strong>Ingelheim</strong> do BrasilQuimica e Farmaceutica Ltda.,São PauloSolana Agro Pecuaria Ltda.,Arapongascanada D R<strong>Boehringer</strong> <strong>Ingelheim</strong>(Canada) Ltd., Burlingtonchile<strong>Boehringer</strong> <strong>Ingelheim</strong> Ltda.,Santiago de ChileDcolumbia D P<strong>Boehringer</strong> <strong>Ingelheim</strong> S.A.,Bogotádenmark D P<strong>Boehringer</strong> <strong>Ingelheim</strong>Danmark A/S, CopenhagenecuadorD<strong>Boehringer</strong> <strong>Ingelheim</strong> delEcuadorCia. Ltda., Quitofrance D PPT <strong>Boehringer</strong> <strong>Ingelheim</strong>Indonesia, Jakartaitaly D P R<strong>Boehringer</strong> <strong>Ingelheim</strong>Italia S.p.A., ReggelloBidachem S.p.A.,Fornovo S. Giovanni<strong>Boehringer</strong> <strong>Ingelheim</strong> ResearchItalia S.a.S., Milanjapan D P RNippon <strong>Boehringer</strong> <strong>Ingelheim</strong>Co. Ltd., TokyoSSP Co. Ltd., Tokyo<strong>Boehringer</strong> <strong>Ingelheim</strong>Vetmedica Japan Co. Ltd.,Tokyo<strong>Boehringer</strong> <strong>Ingelheim</strong>Seiyaku Co. Ltd., Yamagata<strong>Boehringer</strong> <strong>Ingelheim</strong>Japan, Inc., Tokyomexico D P R<strong>Boehringer</strong> <strong>Ingelheim</strong>Promeco S.A. de C.V.,Mexico City<strong>Boehringer</strong> <strong>Ingelheim</strong> Vetmedica,S.A. de C.V., Guadalajarathe netherlands D P<strong>Boehringer</strong> <strong>Ingelheim</strong> Lda.,LisbonUnilfarma Lda., Lisbonsouth africaD<strong>Boehringer</strong> <strong>Ingelheim</strong> (Pty.) Ltd.,Randburg<strong>Ingelheim</strong> Pharmaceuticals (Pty.)Ltd., Randburgspain D P<strong>Boehringer</strong> <strong>Ingelheim</strong>España S.A., Barcelona<strong>Boehringer</strong> <strong>Ingelheim</strong> S.A.,BarcelonaEuropharma S.A., BarcelonaLaboratorios Fher S.A., BarcelonaswedenD<strong>Boehringer</strong> <strong>Ingelheim</strong> AB,StockholmswitzerlandD<strong>Boehringer</strong> <strong>Ingelheim</strong>(Schweiz) GmbH, BaselPharmaton S.A., Luganotaiwan<strong>Boehringer</strong> <strong>Ingelheim</strong>Taiwan Ltd., TaipeiD<strong>Boehringer</strong> <strong>Ingelheim</strong> Ltd.,Bracknellusa D P R<strong>Boehringer</strong> <strong>Ingelheim</strong> Corp.,Ridgefield, Connecticut<strong>Boehringer</strong> <strong>Ingelheim</strong>Pharmaceuticals, Inc.,Ridgefield, Connecticut<strong>Boehringer</strong> <strong>Ingelheim</strong>USA Corporation,Ridgefield, ConnecticutBen Venue Laboratories, Inc.,Bedford, OhioRoxane Laboratories, Inc.,Columbus, Ohio<strong>Boehringer</strong> <strong>Ingelheim</strong>Vetmedica, Inc.,St. Joseph, Missouri<strong>Boehringer</strong> <strong>Ingelheim</strong>Roxane, Inc., Columbus, Ohio<strong>Boehringer</strong> <strong>Ingelheim</strong>Chemicals, Inc.,Petersburg, Virginia<strong>Boehringer</strong> <strong>Ingelheim</strong>Fremont, Inc.,Fremont, Californiavenezuela<strong>Boehringer</strong> <strong>Ingelheim</strong> C.A.,CaracasD<strong>Boehringer</strong> <strong>Ingelheim</strong>France S.A.S., ParisLabso Chimie Fine S.A.R.L.,Blanquefort<strong>Boehringer</strong> <strong>Ingelheim</strong> B.V.,Alkmaar<strong>Boehringer</strong> <strong>Ingelheim</strong>Animal Health Operations B.V.,Alkmaarthailand<strong>Boehringer</strong> <strong>Ingelheim</strong>(Thai) Ltd., BangkokDOverview of the major consolidated companies 41
C. H. <strong>Boehringer</strong> Sohn AG & Co. KG, <strong>Ingelheim</strong>CONSOLIDATED BALANCE SHEETAssets (in millions of EUR) Notes 1) 31.12.<strong>2012</strong> 31.12.2011Intangible assets (3.1) 682 710Tangible assets (3.2) 3,103 3,442Financial assets (3.3) 4,222 3,953Fixed assets 8,007 8,105Inventories (3.4) 2,095 1,998Accounts receivable and other assets (3.5) 3,197 3,126Securities 468 1,932Cash and cash equivalents 1,906 1,971Current assets 7,666 9,027Deferred charges and prepaid expenses 74 69Deferred taxes 1,543 1,457Total assets 17,290 18,658Liabilities and equity (in millions of EUR) Notes 1) 31.12.<strong>2012</strong> 31.12.2011Shareholders‘ capital 178 178Group reserves 4,764 5,806Balance sheet currency conversion difference — 1 6Net income 1,237 1,476Group equity 6,178 7,466Negative difference from acquisition of companies 134 157Provisions (3.6) 7,462 7,128Accounts payable (3.7) 2,887 3,280Liabilities 10,349 10,408Deferred charges 342 353Deferred taxes 287 274Total liabilities and equity 17,290 18,6581)For explanation, see relevant section in the Notes to the consolidated financial statements.42<strong>Boehringer</strong> <strong>Ingelheim</strong> annual report <strong>2012</strong>
- Page 1 and 2:
Value through InnovationCorporate M
- Page 3 and 4:
our businesses66 [ prescription med
- Page 7:
value through innovationperspective
- Page 10 and 11:
56° 40' 59" N, 5° 6' 14" Wglencoe
- Page 12 and 13:
56° 40' 59" N, 5° 6' 14" Wglencoe
- Page 14 and 15:
PERSPECTIVES FORSOCIETYIn all our a
- Page 16 and 17:
50 NATIONSPeople from around 50 nat
- Page 18 and 19:
“RLDP journey: a great learning o
- Page 20 and 21:
SHONA MCDONALD, SHONAQUIP[ south af
- Page 22 and 23:
SEHNAZ LAYIKEL, RUSIHAK[ turkey ]he
- Page 24 and 25:
Thalita Guimaraes joins the “Boeh
- Page 26 and 27:
When handling chemicals, employees
- Page 28 and 29:
11 With its own wastewater treatmen
- Page 30 and 31:
21 Dr Carolyn R. Bertozzi received
- Page 32 and 33:
PERSPECTIVES FOR THE SOCIETYOF TOMO
- Page 34 and 35:
The opening ceremony of IMB:Interac
- Page 36 and 37:
CIRCUIT MECHANICS OF EMOTIONSUnders
- Page 38 and 39:
BIBERACH UNIVERSITY OF APPLIEDSCIEN
- Page 40 and 41:
22° 41' 0" S, 14° 32' 0" Eswakopm
- Page 42 and 43:
22° 41' 0" S, 14° 32' 0" Eswakopm
- Page 44 and 45:
PERSPECTIVES FORMEDICAL INNOVATIONB
- Page 46 and 47:
RESEARCH PARTNERSHIPS WITHACADEMIA
- Page 48 and 49:
collaborate innovate accelerateTRAN
- Page 50 and 51:
GLORIA-AF®Registry programme for p
- Page 52 and 53:
BOEHRINGER INGELHEIM ONCOLOGY FRANC
- Page 54 and 55:
AFATINIB BLOCKS THE ERBB RECEPTORSE
- Page 56 and 57:
HEPTATIS C VIRUS (HCV) INFECTIONHCV
- Page 58 and 59:
1viral entryrnareleasernatranslated
- Page 60 and 61:
12THE MAIN COMPLICATIONS OF DIABETE
- Page 62 and 63:
ASTHMAAsthma is a chronic disease c
- Page 64 and 65:
THERAPEUTIC AREA (TA) REVIEW CORE T
- Page 66 and 67:
6° 59' 15" N, 125° 16' 15" Eapo,
- Page 68 and 69:
icardo f. solitariadistrict manager
- Page 70 and 71:
PERSPECTIVES FORBETTER HEALTHBoehri
- Page 72 and 73:
“My photo shows Frau Röhrigfrom
- Page 74 and 75:
OUR CARDIOVASCULAR PORTFOLIOaggreno
- Page 76 and 77:
HOW ATRIAL FIBRILLATION (AF)LEADS T
- Page 78 and 79:
FINDING THE RIGHT MOLECULE“Findin
- Page 80 and 81:
PATIENTS AT CARDIOVASCULAR RISKMost
- Page 82 and 83:
TRAJENTA® / TRADJENTA®trajenta®
- Page 84 and 85:
WORLD DIABETES DAYWorld Diabetes Da
- Page 86 and 87:
SPIRIVA®: 10 YEARS AND MORE OF CLI
- Page 88 and 89:
BEHAVIOUR CHANGE INTYPE 2 DIABETEST
- Page 90 and 91:
Rapid progress in global healthcare
- Page 92 and 93:
KEY GOALS OF GLOBAL BUSINESS SERVIC
- Page 94 and 95:
“The perspectives that open upune
- Page 96 and 97:
OUR GLOBAL SWITCH TEAMThe Switch un
- Page 98 and 99:
“For me, the photo shows thatthe
- Page 100 and 101:
2 Disposable single use bioreactorw
- Page 102 and 103:
“The hard-working beessuccessfull
- Page 104 and 105:
“There are many things and experi
- Page 106 and 107:
OUR GLOBAL SCIENTIFIC NET WORKIN AN
- Page 108 and 109:
2 31 Scientists in Hannover working
- Page 110 and 111:
“Living and working on a differen
- Page 112 and 113:
1 Phoenix, the first captive-bredOr
- Page 114 and 115:
55° 21' 0" N, 131° 40' 24" Wketch
- Page 116 and 117:
scott zhangstrategic effectiveness
- Page 118 and 119:
PERSPECTIVES FORQUALITY IN OPERATIO
- Page 120 and 121:
With the quality risk management sy
- Page 122 and 123:
In order to ensure patient safety,
- Page 124 and 125:
37° 34' 48" N, 14° 16' 34" Esicil
- Page 126 and 127:
37° 34' 48" N, 14° 16' 34" Esicil
- Page 128 and 129:
PERSPECTIVES FORESTABLISHED MARKETS
- Page 130 and 131: Spain is one of the countries struc
- Page 132 and 133: 21 View of Athens.2 Production site
- Page 134 and 135: 1 View of San Francisco, the leadin
- Page 136 and 137: 211 View of Tokyo with Japan’s hi
- Page 138 and 139: IF YOU HAVE ANY QUERIES OR COMMENTS
- Page 140 and 141: Value through InnovationBusiness Ye
- Page 142 and 143: product portfolio70 [ branded presc
- Page 144 and 145: usiness year 2012our companyOUR COM
- Page 146 and 147: usiness year 2012the shareholders
- Page 148 and 149: usiness year 2012the shareholders
- Page 150 and 151: usiness year 2012 key aspects 2012S
- Page 152 and 153: usiness year 2012 key aspects 2012F
- Page 154 and 155: usiness year 2012 key aspects 2012B
- Page 156 and 157: usiness year 2012corporate bodiesCO
- Page 158 and 159: usiness year 2012group management r
- Page 160 and 161: usiness year 2012group management r
- Page 162 and 163: usiness year 2012group management r
- Page 164 and 165: usiness year 2012group management r
- Page 166 and 167: usiness year 2012group management r
- Page 168 and 169: usiness year 2012group management r
- Page 170 and 171: usiness year 2012group management r
- Page 172 and 173: usiness year 2012group management r
- Page 174 and 175: usiness year 2012group management r
- Page 176 and 177: usiness year 2012group management r
- Page 178 and 179: usiness year 2012consolidated finan
- Page 182 and 183: usiness year 2012consolidated finan
- Page 184 and 185: usiness year 2012consolidated finan
- Page 186 and 187: usiness year 2012consolidated finan
- Page 188 and 189: usiness year 2012consolidated finan
- Page 190 and 191: usiness year 2012consolidated finan
- Page 192 and 193: usiness year 2012consolidated finan
- Page 194 and 195: usiness year 2012consolidated finan
- Page 196 and 197: usiness year 2012consolidated finan
- Page 198 and 199: usiness year 2012consolidated finan
- Page 200 and 201: usiness year 2012consolidated finan
- Page 202 and 203: usiness year 2012consolidated finan
- Page 204 and 205: usiness year 2012consolidated finan
- Page 206 and 207: usiness year 2012auditor’s report
- Page 208 and 209: product portfolioa selection2012PRO
- Page 210 and 211: product portfoliobranded prescripti
- Page 212 and 213: product portfoliobranded prescripti
- Page 214 and 215: product portfoliobranded prescripti
- Page 216 and 217: product portfoliobranded prescripti
- Page 218 and 219: product portfoliobranded prescripti
- Page 220 and 221: product portfolioconsumer health ca
- Page 222 and 223: product portfolioconsumer health ca
- Page 224 and 225: product portfolioconsumer health ca
- Page 226 and 227: product portfolioconsumer health ca
- Page 228 and 229: product portfolioanimal healthIndic
- Page 230 and 231:
product portfolioanimal healthIndic
- Page 232 and 233:
product portfolioanimal healthIndic
- Page 234 and 235:
product portfolioanimal healthIndic
- Page 236 and 237:
usiness year 2012financial data2006
- Page 238:
www.boehringer-ingelheim.comannualr